Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:ADMA Biologics (ADMA) : This specialty immune globulin company which develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases, has seen the Zacks Consensus Estimate for its current year earnings increasing 40% over the last 60 days.Vertex (VERX) : This company which provides tax technology solutions for corporations in retail, leasing, communication and manufactu ...

I specialize in biotech and healthcare investment analysis, integrating clinical expertise with a solid foundation in business strategy. My approach leverages detailed risk-return charts and DCF analyses to clearly communicate the investment potential and associated risks. I advocate for a barbell portfolio strategy, with 90% allocated to secure assets such as Treasuries and broad-market ETFs, and 10% to high-alpha stocks. This balanced approach ensures that all recommendations are made within a context of ...

The latest trading session saw Adma Biologics (ADMA) ending at $19.44, denoting a -0.26% adjustment from its last day's close. This change lagged the S&P 500's 0.4% gain on the day. At the same time, the Dow added 0.62%, and the tech-heavy Nasdaq gained 0.6%.The the stock of infectious disease drug developer has risen by 13.05% in the past month, leading the Medical sector's loss of 2.27% and the S&P 500's gain of 1.71%.Market participants will be closely following the financial results of Adma Biologics in ...

ADMA Biologics, Inc.’s (ADMA) shares skyrocketed 76.2% in the past three months compared with the industry’s growth of 9.6%. The stock also hit a new 52-week high of $19.34 on Sept. 9.The stupendous rally can be attributed to the company’s impressive performance year to date. Sales in the first half increased 61%. Last month, the company also raised its annual guidance for 2024 and 2025 revenues and net income, based on the continuous growth of its unique and proprietary immunoglobulin, Asceniv.ADMA Outperf ...

Group 1 - ADMA Biologics, Inc. will join the S&P SmallCap 600 index effective September 23, 2024, which is expected to enhance the company's visibility and share liquidity [1] - The S&P SmallCap 600 index measures the small-cap segment of the U.S. equity market and consists of 600 companies that meet specific inclusion criteria [1] - ADMA Biologics specializes in manufacturing, marketing, and developing specialty biologics for immunodeficient patients and those at risk for infectious diseases [2] Group 2 - ADMA currently markets three FDA-approved plasma-derived biologics: BIVIGAM®, ASCENIV™, and NABI-HB® for treating immune deficiencies and preventing certain infectious diseases [2] - The company operates an FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida, and has a subsidiary, ADMA BioCenters, for plasma collection [2] - ADMA holds numerous U.S. and foreign patents related to its products and product candidates, focusing on niche patient populations [2]

After reaching an important support level, Adma Biologics (ADMA) could be a good stock pick from a technical perspective. ADMA surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.The 20-day simple moving average is a well-liked trading tool because it provides a look back at a stock's price over a 20-day period. Additionally, short-term traders find this SMA very beneficial, as it smooths out short-term price trends and shows more trend reversal signals than longer-term ...

Have you been paying attention to shares of Adma Biologics (ADMA) ? Shares have been on the move with the stock up 11.7% over the past month. The stock hit a new 52-week high of $19.34 in the previous session. Adma Biologics has gained 306.6% since the start of the year compared to the 10.3% move for the Zacks Medical sector and the 0% return for the Zacks Medical - Biomedical and Genetics industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it hasn't mi ...

Company Overview - ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics for immunodeficient patients and those at risk for infectious diseases [2] - The company currently manufactures and markets three FDA-approved plasma-derived biologics: BIVIGAM® for primary humoral immunodeficiency, ASCENIV™ for primary immunodeficiency, and NABI-HB® for enhanced immunity against hepatitis B [2] - ADMA operates an FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida, and also functions as an FDA-approved source plasma collector through its subsidiary, ADMA BioCenters [2] Upcoming Events - Adam Grossman, President and CEO of ADMA, will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on September 17, 2024, at 3:05 p.m. ET [1] - A live audio webcast of the event will be available on the company's investor website, with an archived version accessible approximately two hours post-event [1]

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Adma Biologics (ADMA) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.Adma Biologics is a member of our Medical group, which includes 1017 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the ind ...

ADMA Biologics, Inc.’s (ADMA) shares have surged 31.4% in a month compared with the industry’s growth of 1.4%. The stock hit its 52-week high of $17.87 on Aug 14.The significant growth can be attributed to the company’s better-than-expected second-quarter results, wherein both the top and bottom-lines beat their estimates. The company also raised its annual guidance for 2024 and 2025 revenues and net income, based on the continuous growth of its unique and proprietary immunoglobulin, Asceniv.ADMA expects to ...